GlobeNewswire·Nov 2, 2026, 8:00 AM ET

Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

ALMR NHLTY

Alamar Biosciences & Nightingale Health launched the UK Biobank vanguard study (UKB-PRISM) to measure blood-based biomarkers for neurodegenerative diseases.
The study utilizes Alamar's NULISA platform to detect low-abundance proteins in 80,000 blood samples from UK Biobank participants.
Nightingale Health laboratories will conduct the analysis to create one of the world's largest open-access resources on early molecular indicators of neurodegeneration.
Researchers aim to identify shared biological roots of Alzheimer's & Parkinson's disease years before symptoms emerge to enable earlier intervention.
Funding for the study is provided by Alzheimer's Research UK, LifeArc, & other partners, with completion expected by the end of 2027.
Upon completion, the full dataset will be combined with UK Biobank's imaging, genetic, metabolomic, & lifestyle data for global researcher access via the Research Analysis Platform.
Dr. Adam Lewandowski of UK Biobank emphasized the study's role in providing a snapshot of proteins associated with brain health decades prior to diagnosis.
Yuling Luo, CEO of Alamar Biosciences, stated the NULISA platform enables measurement of previously out-of-reach protein signals at population scale.
Teemu Suna, CEO of Nightingale Health, noted the study builds on existing metabolomic data from 500,000 participants to support preventive healthcare.
Dr. Sheona Scales of Alzheimer's Research UK highlighted the potential for the study to transform understanding of dementia progression & lead to better treatments.
Sam Barrell of LifeArc indicated the data will assist in investigating rare dementias by combining large-scale protein measurements with extensive health records.